当前位置:首页 > 报告详情

Illumina-JPM-Conference-January-2025.pdf

上传人: c** 编号:603985 2025-02-03 27页 1.03MB

1、 2025 Illumina,Inc.All rights reserved.CEOJacob Thaysen,Ph.D.43rdAnnual J.P.Morgan Healthcare ConferenceJanuary 14,2025J.P.Morgan Healthcare Conference 2025Cautionary Notes on Forward Looking StatementsThis release may contain forward-looking statements that involve risks and uncertainties.Among the

2、 important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are:Our ability to meet our revenue and earnings per share growth targets;Changes in the rate of growth in the markets we serve;The volume,timing and

3、mix of customer orders among our products and services;Our ability to adjust our operating expenses to align with our revenue expectations;Our ability to manufacture robust instrumentation and consumables;The success of products and services competitive with our own;Challenges inherent in developing

4、,manufacturing,and launching new products and services,including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components;The impact of recently launched or pre-announced products and services on existing products and services;Our ability to reali

5、ze the anticipated benefits from prior or future actions to streamline and improve our R&D processes,reduce our operating expenses and maximize our revenue growth;To deploy new products,services,and applications,and to expand the markets for our technology platforms;Our ability to obtain approval by

6、 third-party payors to reimburse patients for our products;Our ability to obtain regulatory clearance for our products from government agencies;Our ability to successfully partner with other companies and organizations to develop new products,expand markets,and grow our business;Uncertainty,or adver

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Illumina公司CEO Jacob Thaysen在2025年1月14日J.P. Morgan Healthcare Conference上的演讲内容。主要内容包括: 1. Illumina公司概述:Illumina是全球领先的基因组测序和分析公司,拥有超过165个国家的客户,2024财年收入约43.3亿美元,自由现金流约10.7亿美元。 2. 2024财年初步结果:2024财年收入同比下降2%,但第四季度收入同比增长1%,非GAAP每股收益预计在0.91-0.93美元之间。 3. 2025财年展望:预计2025财年收入在42.8-44亿美元之间,非GAAP税率为24%,非GAAP每股收益增长10%以上。 4. 战略执行:重点包括NovaSeq X系列测序平台的推广,多组学业务的发展,以及服务、软件和数据业务的扩展。 5. 未来规划:Illumina将继续专注于客户中心、推动NGS生态系统发展、未来创新管线和商业运营卓越,以实现可持续、盈利的增长。
Illumina的CEO是谁? Illumina在2025年的收入目标是多少? Illumina如何实现从基因组学到多组学的转变?
客服
商务合作
小程序
服务号
折叠